Results 181 to 190 of about 611,895 (310)

Recombinant DNA Research: Proposed Actions Under the Guidelines

open access: yes, 1997
National Institutes of Health [NIH] (United States). Office of Recombinant DNA Activities
core  

Bioprinted Tumor Microenvironment Models Reveal Immune Evasion and Guide CAR‐NK Therapeutic Strategies

open access: yesAdvanced Science, EarlyView.
This study presents a 3D embedded bioprinting platform that recapitulates key stromal features of the tumor microenvironment using fibroblasts and lung‐derived ECM. The model enables functional assessment of CAR‐NK cells and provides a versatile tool to support the development of next‐generation immunotherapeutic strategies against solid tumors ...
Dahong Kim   +10 more
wiley   +1 more source

Recombinant DNA Advisory Committee (minutes of meeting 6 October 1989)

open access: yes, 1989
National Institutes of Health [NIH] (United States). Recombinant DNA Advisory Committee
core  

UCHL3 Regulates Subgenomic Flaviviral RNA Condensates to Promote Virus Propagation

open access: yesAdvanced Science, EarlyView.
ABSTRACT Flavivirus subgenomic RNAs (sfRNAs) antagonise antiviral defences, yet how sfRNAs are organized and maintained in cells remains poorly understood. Here we identify ubiquitin C‐terminal hydrolase L3 (UCHL3) as a post‐translational regulator of flavivirus sfRNA stability and function.
Oscar Trejo‐Cerro   +7 more
wiley   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

open access: yesAdvanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy